International Journal of Endocrinology / 2014 / Article / Tab 2

Clinical Study

Effectiveness of Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion for Children with Type 1 Diabetes Mellitus in Clinical Practice

Table 2

Glycosylated hemoglobin (HbA1c) levels, poor glycemic control rates, insulin dosages, BMI, and frequency of blood glucose monitoring in the experimental (1A, 2A) and control (1B, 2B) groups.

  T0T1T2T3T4/T5

HbA1c level (%)
 Group 1A8.03 ± 1.417.35 ± 1.247.37 ± 1.007.61 ± 1.227.61 ± 1.15
 Group 1B8.01 ± 1.927.89 ± 2.058.21 ± 2.058.41 ± 2.048.72 ± 1.81
0.400.10<0.01<0.01<0.01
 Group 2A8.39 ± 1.238.49 ± 1.408.36 ± 1.259.03 ± 1.599.24 ± 1.43
 Group 2B8.67 ± 1.449.04 ± 1.969.19 ± 1.798.96 ± 1.949.28 ± 1.75
0.870.480.040.920.40
Poor glycemic control rate (%)
 Group 1A1811.54.913.215.4
 Group 1B22.12432.828.632.7
0.520.04<0.010.030.04
 Group 2A30.426.121.747.845
 Group 2B45.743.55037.854.1
0.230.160.020.430.51
Insulin dosage (U/kg/d)
 Group 1A0.59 ± 0.360.54 ± 0.290.58 ± 0.260.68 ± 0.170.76 ± 0.19
 Group 1B0.39 ± 0.240.41 ± 0.230.47 ± 0.220.57 ± 0.230.70 ± 0.25
<0.01<0.01<0.01<0.01<0.01
 Group 2A0.58 ± 0.270.72 ± 0.270.79 ± 0.250.82 ± 0.280.84 ± 0.16
 Group 2B0.66 ± 0.230.69 ± 0.230.71 ± 0.210.74 ± 0.200.83 ± 0.24
0.190.420.240.160.67
BMI (kg/m2)
 Group 1A16.74 ± 2.2617.17 ± 2.0017.25 ± 2.0117.61 ± 1.2217.61 ± 1.15
 Group 1B16.57 ± 1.9216.57 ± 2.0816.60 ± 2.0716.96 ± 2.0717.21 ± 2.49
0.610.020.020.030.53
 Group 2A17.54 ± 1.9718.13 ± 1.9918.70 ± 2.6718.75 ± 2.3419.50 ± 3.08
 Group 2B17.12 ± 2.4517.39 ± 2.5417.73 ± 2.4117.73 ± 2.5717.62 ± 2.59
0.480.07<0.010.030.05
Blood glucose monitoring ≥4 times/day (%)
 Group 1A76.3071.8063.4043.2040.00
 Group 1B62.0054.0051.0038.5047.90
0.050.090.240.650.49
 Group 2A70.0066.7042.9033.3028.60
 Group 2B31.3031.3030.8021.408.30
0.130.060.520.470.18

*Group 1A versus group 1B; group 2A versus group 2B; versus baseline.